Plasma neuropeptide Y levels in Chinese patients with primary insomnia

Sleep and Breathing

Volumn 19, Issue 2, 2015, Pages 617-622

  Huang, Qiaoting ^a   Liao, Jiwu ^a   Liu, Yaping ^b   Liang, Huajun ^b   Ma, Ping ^a   Pan, Jiyang ^a  

^a JINAN UNIVERSITY   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Neuropeptide Y; Primary insomnia; Sleep quality

Indexed keywords

NEUROPEPTIDE Y;

ADULT; BLOOD; CHINA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INSOMNIA; MALE; MIDDLE AGED; REFERENCE VALUE; STATISTICS;

ADULT; CHINA; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPEPTIDE Y; REFERENCE VALUES; SLEEP INITIATION AND MAINTENANCE DISORDERS; STATISTICS AS TOPIC;

EID: 84939879758     PISSN: 15209512     EISSN: 15221709     Source Type: Journal    
DOI: 10.1007/s11325-014-1059-9     Document Type: Article

References (34)

1. American Psychiatric Association (1994) Manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DC
2. Ohayon MM (1997) Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing between insomnia related to mental disorders from sleep disorders. J Psychiatr Res 31(3):333–346
3. Ancoli IS, Roth T (1999) Characteristics of insomnia in the United States: results of the 1991 National Sleep Foundation Survey. Sleep 22(2):347
4. Shekleton JA, Rogers NL, Rajaratnam SMW (2010) Searching for the daytime impairments of primary insomnia. Sleep Med Rev 14(1):47–60
5. Ohayon MM (2002) Epidemiology of insomnia: what we know and what we still need to learn. Sleep Med Rev 6(2):97–111
6. Rocha FL, Hara C, Rodrigues CV, Costa MA, Costa ÉC, Fuzikawa C, Santos VG (2005) Is insomnia a marker for psychiatric disorders in general hospitals? Sleep Med 6(6):549–553
7. Daley M, Morin CM, LeBlanc M, Grégoire J, Savard J (2009) The economic burden of insomnia: direct and indirect costs for individuals with insomnia syndrome, insomnia symptoms, and good sleepers. Sleep 32(1):55–64
8. Heilig M, Widerlo v E (1990) Neuropeptide Y: an overview of central distribution, functional aspects, and possible involvement in neuropsychiatric illnesses. Acta Psychiatr Scand 82(2):95–114
9. Balasubramaniam A (2002) Clinical potentials of neuropeptide Y family of hormones. Am J Surg 183(4):430–434
10. Ehlers CL, Somes C, Lopez A, Kirby D, Rivier JE (1997) Electrophysiological actions of neuropeptide Y and its analogs: new measures for anxiolytic therapy? Neuropsychopharmacology 17(1):34–43
11. Ehlers CL, Somes C, Seifritz E, Rivier JE (1997) CRF/NPY interactions: a potential role in sleep dysregulation in depression and anxiety. Dep Anx 6(1):1–9
12. Antonijevic IA, Murck H, Bohlhalter S, Frieboes RM, Holsboer F, Steiger A (2000) NPY promotes sleep and inhibits ACTH and cortisol release in young men. Neuropharmacology 39(8):1474–1481
13. Held K, Antonijevic IA, Murck H, Künzel H, Steiger A (2006) Neuropeptide Y (NPY) shortens sleep latency and enhances prolactin but does not suppress ACTH and cortisol in depressed patients and controls. Psychoneuroendocrinology 31(1):100–107
14. Steiger A (2007) Neurochemical regulation of sleep. J Psychiatr Res 41(7):537–552
15. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The mini-international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59(20):22–33
16. Si TM, Shu L, Dang WM, Su YA, Chen JX, Dong WT, Kong QM, Zhang WH (2009) Evaluation of the reliability and validity of Chinese version of the mini-international neuropsychiatric interview in patients with mental disorders. Chin Ment Health J 23(7):493–497
17. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ (1989) The Pittsburgh sleep quality index: a new instrument for psychiatric practice and research. Psychiatr Res 28(2):193–213
18. Wang XD, Wang XL, Ma H (1999) Handbook of mental health assessment (Supplement). Chinese Mental Health Journal: 375-378
19. Beck AT, Beck RW (1972) Screening depressed patients in family practice: a rapid technic. Postgrad Med 52(6):81–85
20. Wang XD, Wang XL, Ma H (1999) Handbook of mental health assessment (Supplement). Chinese Mental Health Journal: 191-194
21. Spielberger CD, Gorsuch RL (1983) Manual for the State-trait Anxiety Inventory (form Y) (“self-evaluation Questionnaire”). Consulting Psychologists Press
22. Wang XD, Wang XL, Ma H (1999) Handbook of mental health assessment (Supplement). Chinese Mental Health Journal: 238-241
23. Fuxe K, Agnati LF, Härfstrand A, Zini I, Tatemoto K, Pich EM, Hökfelt T, Mutt V, Terenius L (1983) Central administration of neuropeptide Y induces hypotension bradypnea and EEG synchronization in the rat. Acta Physiol Scand 118(2):189–192
24. Irwin M, Brown M, Patterson T, Hanger R, Mascovich A, Grant I (1991) Neuropeptide Y and natural killer cell activity: findings in depression and Alzheimer caregiver stress. FASEB J 5(15):3100–3107
25. Hashimoto H, Onishi H, Koide S, Kai T, Yamagami S (1996) Plasma neuropeptide Y in patients with major depressive disorder. Neurosci Lett 216(1):57–60
26. Stein MB, Hauger RL, Dhalla KS, Chartier MJ, Asmundson GJ (1996) Plasma neuropeptide Y in anxiety disorders: findings in panic disorder and social phobia. Psychiatr Res 59:183–188
27. Bowers ME, Choi DC, Ressler KJ (2012) Neuropeptide regulation of fear and anxiety: implications of cholecystokinin, endogenous opioids, and neuropeptide Y. Physiol Behav 107(5):699–710
28. Sah R, Geracioti TD (2013) Neuropeptide Y and posttraumatic stress disorder. Mol Psychiatr 18(6):646–655
29. Brunani A, Invitti C, Dubini A, Piccoletti R, Bendinelli P, Maroni P, Pezzoli G, Ramella G, Calogero A, Cavagnini F (1995) Cerebrospinal fluid and plasma concentrations of SRIH, beta-endorphin, CRH, NPY and GHRH in obese and normal weight subjects. Int J Obes Relat Metab Disord 19(1):17–21
30. Grouzmann E, Borgeat A, Fathi M, Gaillard RC, Ravussin P (2000) Plasma and cerebrospinal fluid concentrations of neuropeptide Y, serotonin, and catecholamines in patients under protocol or isoflurane anesthesia. Can J Physiol Pharmacol 78(2):100–107
31. Nam SY, Kratzsch J, Kim KW, Kim KR, Lim SK, Marcus C (2001) Cerebrospinal fluid and plasma concentrations of leptin, NPY, and alpha-MSH in obese women and their relationship to negative energy balance. J Clin Endocr Metab 86(10):4849–4853
32. Baker DG, Bertram TM, Patel PM, Barkauskas DA, Clopton P, Patel S, Geracioti TD Jr, Haji U, O’Connor DT, Nievergelt CM, Hauger RL (2013) Characterization of cerebrospinal fluid (CSF) and plasma NPY levels in normal volunteers over a 24-h timeframe. Psychoneuroendocrinology 38(10):2378–2382
33. Guo X, Jiao F, Zhang X (2006) Neuropeptide Y levels in plasma and cerebrospinal fluid of children with convulsive diseases and its clinical significance. Chin J Pract Pedia 21(11):840–842
34. Dötsch J, Adelmann M, Englaro P, Dötsch A, Hänze J, Blum WF, Kiess W, Rascher W (1997) Relation of leptin and neuropeptide Y in human blood and cerebrospinal fluid. J Neurol Sci 151(2):185–188